{"id":"placebo-insulin-icodec","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL4594581","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin icodec is a novel insulin analog engineered with a fatty acid chain that enables once-weekly subcutaneous dosing through enhanced albumin binding and extended half-life. It mimics endogenous insulin's mechanism by activating insulin receptors on muscle, adipose, and hepatic cells to facilitate glucose homeostasis. The extended duration of action allows for flexible dosing intervals while maintaining stable glycemic control.","oneSentence":"Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:27:43.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Type 1 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04795531","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-24","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT02964104","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-11-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT02148861","phase":"PHASE1","title":"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-05-26","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo insulin icodec","genericName":"Placebo insulin icodec","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}